$ONCO
Onconetix, Inc.

2022 Q3 Form 10-Q Financial Statement

#000121390022048105 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.694M $3.001M $1.616M
YoY Change 226.18% 499.95%
% of Gross Profit
Research & Development $1.175M $1.293M $455.1K
YoY Change 335.48% 144.26%
% of Gross Profit
Depreciation & Amortization $1.850K $1.760K $1.300K
YoY Change 46.83% -29.03%
% of Gross Profit
Operating Expenses $3.870M $4.295M $2.071M
YoY Change 253.1% 442.1%
Operating Profit -$3.870M -$4.295M -$2.071M
YoY Change 253.1% 442.1%
Interest Expense $3.070K $30.30K
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.072K $6.900M
YoY Change
Pretax Income -$3.867M -$4.265M -$2.071M
YoY Change 252.82% 281.43%
Income Tax
% Of Pretax Income
Net Earnings -$3.867M -$4.265M -$2.071M
YoY Change 252.82% 438.27% 535.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.27 -$0.36 -$0.34
Diluted Earnings Per Share -$0.27 -$0.36 -$326.6K
COMMON SHARES
Basic Shares Outstanding 13.58M shares 12.00M shares 6.339M shares
Diluted Shares Outstanding 14.34M shares 12.00M shares 6.339M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.14M $22.24M $18.61M
YoY Change 962.6% 506.14%
Cash & Equivalents $29.14M $22.24M $18.61M
Short-Term Investments
Other Short-Term Assets $880.1K $1.252M $328.8K
YoY Change 49.33% 224.85%
Inventory
Prepaid Expenses $703.8K $1.013M
Receivables
Other Receivables
Total Short-Term Assets $30.05M $23.51M $19.10M
YoY Change 793.44% 476.75%
LONG-TERM ASSETS
Property, Plant & Equipment $15.93K $17.78K $15.40K
YoY Change 33.56% 34.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $93.95K $101.6K $217.1K
YoY Change 103.22% 9.83%
Total Long-Term Assets $109.9K $119.3K $232.5K
YoY Change 88.93% 12.95%
TOTAL ASSETS
Total Short-Term Assets $30.05M $23.51M $19.10M
Total Long-Term Assets $109.9K $119.3K $232.5K
Total Assets $30.16M $23.63M $19.34M
YoY Change 781.47% 465.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $834.3K $973.0K $907.5K
YoY Change 216.19% 1649.0%
Accrued Expenses $3.555M $2.080M $1.893M
YoY Change 568.1% 378.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.431M $3.059M $2.801M
YoY Change 456.72% 523.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.431M $3.059M $2.801M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.431M $3.059M $2.801M
YoY Change 456.72% 523.77%
SHAREHOLDERS EQUITY
Retained Earnings -$16.16M -$12.29M
YoY Change
Common Stock $147.00 $122.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.73M $20.57M $16.53M
YoY Change
Total Liabilities & Shareholders Equity $30.16M $23.63M $19.34M
YoY Change 781.47% 465.03%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.867M -$4.265M -$2.071M
YoY Change 252.82% 438.27% 535.6%
Depreciation, Depletion And Amortization $1.850K $1.760K $1.300K
YoY Change 46.83% -29.03%
Cash From Operating Activities -$1.829M -$3.182M -$886.1K
YoY Change 150.4% 397.76%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$4.140K -$5.200K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$4.140K -$5.200K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.724M 6.819M 17.57M
YoY Change -4528.7%
NET CHANGE
Cash From Operating Activities -1.829M -3.182M -886.1K
Cash From Investing Activities 0.000 -4.140K -5.200K
Cash From Financing Activities 8.724M 6.819M 17.57M
Net Change In Cash 6.895M 3.633M 16.68M
YoY Change -843.38% -668.22%
FREE CASH FLOW
Cash From Operating Activities -$1.829M -$3.182M -$886.1K
Capital Expenditures $0.00 -$4.140K -$5.200K
Free Cash Flow -$1.829M -$3.178M -$880.9K
YoY Change 150.4% 397.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41294
dei Entity Registrant Name
EntityRegistrantName
Blue Water Vaccines Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2262816
dei Entity Address Address Line1
EntityAddressAddressLine1
201 E. Fifth Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1900
dei Entity Address City Or Town
EntityAddressCityOrTown
Cincinnati
dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
45202
dei City Area Code
CityAreaCode
(513)
dei Local Phone Number
LocalPhoneNumber
620-4101
dei Security12b Title
Security12bTitle
Common stock, $0.00001 par value
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
dei Trading Symbol
TradingSymbol
BWV
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13579399 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22242183 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1928474 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1013004 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234551 usd
CY2022Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
238804 usd
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
757646 usd
CY2022Q2 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
20364 usd
CY2021Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
152524 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
23514355 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
3073195 usd
CY2022Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
73974 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17780 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11502 usd
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
27588 usd
CY2022Q2 us-gaap Assets
Assets
23633697 usd
CY2021Q4 us-gaap Assets
Assets
3084697 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
972971 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
582605 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2080392 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1055515 usd
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5373 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3058736 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1638120 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 bwv Preferred Stock Shares Designated
PreferredStockSharesDesignated
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 bwv Preferred Stock Shares Designated
PreferredStockSharesDesignated
1150000 shares
CY2022Q2 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0 usd
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1146138 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1146138 shares
CY2021Q4 bwv Preferred Stock Value1
PreferredStockValue1
11 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12229399 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3200000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
122 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
32 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32866752 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7403204 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12291913 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5956670 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20574961 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1446577 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23633697 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3084697 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3001418 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
262732 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4616987 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
500276 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1293467 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
529542 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1748559 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
617779 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
4294885 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
792274 usd
us-gaap Operating Expenses
OperatingExpenses
6365546 usd
us-gaap Operating Expenses
OperatingExpenses
1118055 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4294885 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-792274 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6365546 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1118055 usd
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-30303 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-30303 usd
CY2022Q2 us-gaap Other Operating Income
OtherOperatingIncome
30303 usd
us-gaap Other Operating Income
OtherOperatingIncome
30303 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4264582 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-792274 usd
us-gaap Net Income Loss
NetIncomeLoss
-6335243 usd
us-gaap Net Income Loss
NetIncomeLoss
-1118055 usd
CY2021Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
139217 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
96359 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
276904 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4264582 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-931491 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6431602 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1394959 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
51304 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18400000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11995832 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3200000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9226621 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3200000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1446577 usd
CY2022Q1 bwv Issuance Of Common Stock In Initial Public Offering Net
IssuanceOfCommonStockInInitialPublicOfferingNet
2900000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17138840 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
19332 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2070661 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
16534088 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6858328 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1447127 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4264582 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20574961 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4733770 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
41721 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-325781 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
4449710 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
34924 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-792274 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
3692360 usd
us-gaap Net Income Loss
NetIncomeLoss
-6335243 usd
us-gaap Net Income Loss
NetIncomeLoss
-1118055 usd
us-gaap Depreciation
Depreciation
3061 usd
us-gaap Depreciation
Depreciation
2478 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1466459 usd
us-gaap Share Based Compensation
ShareBasedCompensation
76645 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-30303 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
778453 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
77500 usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
30000 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
7840 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
12437 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
73974 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-92467 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
27588 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-15000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1223613 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
434728 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
491760 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-13037 usd
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-9642 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4068508 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-639353 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9339 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9339 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-639353 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1928474 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4308821 usd
CY2022Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
6900000 usd
us-gaap Debt Instrument Term
DebtInstrumentTerm
P1Y
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
-926972 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7319462 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
349630 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24391556 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
20313709 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22242183 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3669468 usd
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
187500 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
45 usd
bwv Initial Public Offering Costs Included In Accounts Payable
InitialPublicOfferingCostsIncludedInAccountsPayable
75828 usd
bwv Recognition Of Contingent Warrant Liability Upon Issuance Of Common Stock In Private Placement
RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement
35676 usd
bwv Payment Of Accrued Bonus Through Related Party Receivable
PaymentOfAccruedBonusThroughRelatedPartyReceivable
140000 usd
bwv Exercise Of Prefunded Warrants
ExerciseOfPrefundedWarrants
6 usd
CY2022Q1 bwv Initial Public Offering Shares
InitialPublicOfferingShares
2222222 shares
CY2022Q1 bwv Price Per Share
PricePerShare
9
CY2022Q1 bwv Initial Public Offering
InitialPublicOffering
Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were $17.1 million.
CY2022Q1 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
5626365 shares
CY2022Q2 us-gaap Investments And Cash
InvestmentsAndCash
22200000 usd
CY2022Q2 us-gaap Other Additional Capital
OtherAdditionalCapital
20500000 usd
CY2022Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
12300000 usd
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
5373 usd
CY2022Q2 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
35676 usd
us-gaap Servicing Liability At Fair Value Other Changes In Fair Value
ServicingLiabilityAtFairValueOtherChangesInFairValue
30303 usd
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
5373 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to the valuation of common stock, stock-based compensation, valuation of the contingent warrant liability, judgments used in the evaluation of potential loss contingencies, accrued research and development expenses and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of June 30, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.46875
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.17 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0286 pure
CY2022Q2 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
800000 usd
CY2021Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
300000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd
bwv Options To Purchase Shares Of Common Stock
OptionsToPurchaseSharesOfCommonStock
1495180 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.56
CY2022Q2 bwv Options To Purchase Shares Of Common Stock
OptionsToPurchaseSharesOfCommonStock
1495180 shares
CY2021Q2 bwv Options To Purchase Shares Of Common Stock
OptionsToPurchaseSharesOfCommonStock
780640 shares
bwv Options To Purchase Shares Of Common Stock
OptionsToPurchaseSharesOfCommonStock
780640 shares
CY2021Q2 bwv Series Seed Preferred Stock
SeriesSeedPreferredStock
4584552 shares
bwv Series Seed Preferred Stock
SeriesSeedPreferredStock
4584552 shares
CY2022Q2 bwv Warrants Issued Upon Close Of Ipo
WarrantsIssuedUponCloseOfIPO
111111 shares
bwv Warrants Issued Upon Close Of Ipo
WarrantsIssuedUponCloseOfIPO
111111 shares
CY2022Q2 bwv Private Placement Warrants
PrivatePlacementWarrants
1251661 shares
bwv Private Placement Warrants
PrivatePlacementWarrants
1251661 shares
CY2022Q2 bwv Total Number Of Shares
TotalNumberOfShares
2857952 shares
CY2021Q2 bwv Total Number Of Shares
TotalNumberOfShares
5365192 shares
bwv Total Number Of Shares
TotalNumberOfShares
2857952 shares
bwv Total Number Of Shares
TotalNumberOfShares
5365192 shares
CY2022Q2 bwv Prepaids Research And Development
PrepaidsResearchAndDevelopment
217337 usd
CY2021Q4 bwv Prepaids Research And Development
PrepaidsResearchAndDevelopment
203910 usd
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
720735 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
4842 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
74932 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
25799 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1013004 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234551 usd
us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
10000 usd
CY2021 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
225000 usd
bwv Accrued Research And Development
AccruedResearchAndDevelopment
497022 usd
CY2021 bwv Accrued Research And Development
AccruedResearchAndDevelopment
300182 usd
CY2022Q2 bwv Accrued Deferred Offering Costs
AccruedDeferredOfferingCosts
187500 usd
CY2021Q4 bwv Accrued Deferred Offering Costs
AccruedDeferredOfferingCosts
246236 usd
CY2022Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
736380 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
234265 usd
CY2022Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
520000 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Fair Value Disclosure
AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
49000 usd
CY2022Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
80490 usd
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
49832 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2080392 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1055515 usd
bwv Oui Agreement Expiration
OUIAgreementExpiration
P10Y
CY2022Q2 us-gaap Taxes And Licenses
TaxesAndLicenses
8000 usd
us-gaap Taxes And Licenses
TaxesAndLicenses
10000 usd
CY2021Q2 us-gaap Taxes And Licenses
TaxesAndLicenses
10000 usd
us-gaap Taxes And Licenses
TaxesAndLicenses
10000 usd
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1150000 shares
CY2022Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.00001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12229399 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12229399 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3200000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3200000 shares
CY2022Q1 bwv Aggregate Purchase Shares
AggregatePurchaseShares
2222222 shares
CY2022Q1 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
9
CY2022Q1 us-gaap Underwriting Expense Ratio
UnderwritingExpenseRatio
0.08 pure
CY2022Q1 us-gaap Other Ownership Interests Offering Costs
OtherOwnershipInterestsOfferingCosts
17100000 usd
CY2022Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
111111 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
10.35
CY2022Q2 us-gaap Other Expenses
OtherExpenses
6900000 usd
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2022Q2 us-gaap Shares Issued
SharesIssued
590406 shares
bwv Aggregate Percentage
AggregatePercentage
0.02 pure
CY2022Q2 bwv Percentage Of Purchase Warrants
PercentageOfPurchaseWarrants
0.06 pure
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.46875
CY2022Q2 bwv Warrants Issuable Shares
WarrantsIssuableShares
70849 shares
CY2022Q2 us-gaap Share Price
SharePrice
6.65
CY2022Q2 bwv Agent Fee Percentage
AgentFeePercentage
0.075 pure
CY2022Q2 bwv Management Fee Percentage
ManagementFeePercentage
0.01 pure
CY2022Q2 bwv Out Of Pocket Expenses
OutOfPocketExpenses
85000 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
70849 shares
CY2022Q2 us-gaap Other Liabilities
OtherLiabilities
36000 usd
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
5000 usd
CY2022Q1 bwv Conversion Price Per Shares
ConversionPricePerShares
1.52
CY2022Q1 bwv Underwritten Public Offering Netting Proceeds
UnderwrittenPublicOfferingNettingProceeds
50000000 usd
CY2022Q1 bwv Offering Price Percentage
OfferingPricePercentage
3 pure
CY2022Q1 bwv Cumulative Dividends Per Share
CumulativeDividendsPerShare
0.08 pure
CY2022Q1 us-gaap Cumulative Dividends
CumulativeDividends
1586162 usd
CY2022Q1 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
1.38
CY2022Q1 us-gaap Shares Issued
SharesIssued
1600000 shares
bwv Issuance Options
IssuanceOptions
104820 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
780640 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.01
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
532787000000 usd
bwv Weighted Average Remaining Contractual Life Outstanding
WeightedAverageRemainingContractualLifeOutstanding
P8Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
714540 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.34
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1495180 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.04
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1653005000000 usd
bwv Weighted Average Remining Contractual Life Outstanding
WeightedAverageReminingContractualLifeOutstanding
P8Y8M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
891722 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1134252000000 usd
bwv Weighted Average Remaining Contractual Life Options Vested And Exercisable
WeightedAverageRemainingContractualLifeOptionsVestedAndExercisable
P8Y6M
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.56
bwv Payment Of Accrued Bonus Through Related Party Receivable
PaymentOfAccruedBonusThroughRelatedPartyReceivable
usd
CY2021Q4 us-gaap Due From Related Parties
DueFromRelatedParties
153000 usd
CY2021 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
140000 usd
bwv Exercise Of Prefunded Warrants
ExerciseOfPrefundedWarrants
usd
CY2022Q2 bwv Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue
1400000 usd
bwv Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue
1500000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1447127 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
34924 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1466459 usd
us-gaap Share Based Compensation
ShareBasedCompensation
76645 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1100000 usd
us-gaap Insured Financial Obligations With Credit Deterioration Remaining Weighted Average Contract Period
InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod
P1Y11M15D
us-gaap Lease Cost
LeaseCost
5500 usd
bwv Rentals Deposit
RentalsDeposit
15000 usd
CY2022Q2 us-gaap Payments For Rent
PaymentsForRent
0 usd
CY2021Q2 us-gaap Payments For Rent
PaymentsForRent
8000 usd
us-gaap Payments For Rent
PaymentsForRent
28000 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company terminated the related party lease in May 2021 and entered into a month-to-month lease in Cincinnati, Ohio, with an unrelated party in April 2021 with monthly payments of approximately $500 per month.
us-gaap Related Party Costs
RelatedPartyCosts
500 usd
CY2022Q2 us-gaap Short Term Lease Payments
ShortTermLeasePayments
14000 usd
us-gaap Loss Contingency Date Of Dismissal
LossContingencyDateOfDismissal
2023-04-30
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
36000 usd
CY2022Q2 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
500000 usd
CY2022Q2 us-gaap Other Commitments Future Minimum Payments Remainder Of Fiscal Year
OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear
56000 usd
bwv Accured Expenses
AccuredExpenses
453000 usd
CY2022Q2 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0 usd
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
63000 usd
CY2021Q2 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
105000 usd
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
210000 usd
CY2022Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
140000 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
100000 usd
CY2022Q2 us-gaap Due From Related Parties
DueFromRelatedParties
20000 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
bwv Total Intrinsic Value Forfeited Cancelledin Dollars Per Share
TotalIntrinsicValueForfeitedCancelledinDollarsPerShare
usd
bwv Weighted Average Remaining Contractual Life Forfeited Cancelled
WeightedAverageRemainingContractualLifeForfeitedCancelled
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
bwv Initial Public Offering Costs Included In Accounts Payable
InitialPublicOfferingCostsIncludedInAccountsPayable
usd
bwv Recognition Of Contingent Warrant Liability Upon Issuance Of Common Stock In Private Placement
RecognitionOfContingentWarrantLiabilityUponIssuanceOfCommonStockInPrivatePlacement
usd
us-gaap Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage
DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
1 pure
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.001
us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
2.546
bwv Description Of Wainwright Placement Agent Fees
DescriptionOfWainwrightPlacementAgentFees
The Company agreed to pay Wainwright a placement agent fee and management fee equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the August Private Placement and reimburse certain out-of-pocket expenses up to an aggregate of $85,000. In addition, the Company issued warrants to Wainwright (the “August Wainwright Warrants”) to purchase up to 220,997 shares of common stock. The August Wainwright Warrants are in substantially the same form as the preferred investment options, except that the exercise price is $3.3938. Further, upon any exercise for cash of any preferred investment options, the Company agreed to issue to Wainwright additional warrants to purchase the number of Shares equal to 6.0% of the aggregate number of Shares underlying the preferred investment options that have been exercised, also with an exercise price of $3.3938.
us-gaap Credit Derivative Liquidation Proceeds Percentage
CreditDerivativeLiquidationProceedsPercentage
0.02 pure
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11995832 shares
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2022Q2 bwv Issuance Of Common Stock And Warrants In Private Placement Net
IssuanceOfCommonStockAndWarrantsInPrivatePlacementNet
1400000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
usd
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2021Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
bwv Weighted Average Remaining Contractual Life Granted
WeightedAverageRemainingContractualLifeGranted
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
usd
CY2022Q2 bwv Series Seed Preferred Stock
SeriesSeedPreferredStock
shares
bwv Series Seed Preferred Stock
SeriesSeedPreferredStock
shares
CY2021Q2 bwv Warrants Issued Upon Close Of Ipo
WarrantsIssuedUponCloseOfIPO
shares
bwv Warrants Issued Upon Close Of Ipo
WarrantsIssuedUponCloseOfIPO
shares
CY2021Q2 bwv Private Placement Warrants
PrivatePlacementWarrants
shares
bwv Private Placement Warrants
PrivatePlacementWarrants
shares
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Fair Value Disclosure
AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
usd
bwv Intrinsic Value Granted
IntrinsicValueGranted
usd
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
bwv Weighted Average Remaining Contractual Life Exercised
WeightedAverageRemainingContractualLifeExercised
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001782107

Files In Submission

Name View Source Status
0001213900-22-048105-index-headers.html Edgar Link pending
0001213900-22-048105-index.html Edgar Link pending
0001213900-22-048105.txt Edgar Link pending
0001213900-22-048105-xbrl.zip Edgar Link pending
bwv-20220630.xsd Edgar Link pending
f10q06223ex31-1_bluewater.htm Edgar Link pending
f10q06223ex31-2_bluewater.htm Edgar Link pending
f10q06223ex32-1_bluewater.htm Edgar Link pending
f10q06223ex32-2_bluewater.htm Edgar Link pending
f10q0622_bluewater.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
bwv-20220630_lab.xml Edgar Link unprocessable
bwv-20220630_def.xml Edgar Link unprocessable
bwv-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0622_bluewater_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bwv-20220630_cal.xml Edgar Link unprocessable